Digest Network Come funziona
Network
/
Società
Se
Non verificato

Seaport Therapeutics

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

23 comunicati stampa

Guarda tutti i comunicati
03/03/2026
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
20/02/2026
Eventi
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
18/02/2026
Psichiatria
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
05/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Finanza
Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
08/12/2025
Eventi
Medicina alternativa
Salute
Medicina - Varie
Seaport Therapeutics Presents Data Further Validating Glyph™ Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
04/12/2025
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Web e Social Network
Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Web e Social Network
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
18/09/2025
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Seaport Therapeutics to Participate in Upcoming Investor Conferences
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
11/09/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Industria
Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0
17/07/2025
Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
Fonte
Seaport Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0